|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0027819,
umls-concept:C0040732,
umls-concept:C0087111,
umls-concept:C0178602,
umls-concept:C0205269,
umls-concept:C0205390,
umls-concept:C0439859,
umls-concept:C1292724,
umls-concept:C1513784,
umls-concept:C1513822,
umls-concept:C1880171,
umls-concept:C2603343
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-1-19
|
|
pubmed:abstractText |
To determine the maximum-tolerated dose (MTD) and toxicity of iodine-131-metaiodobenzylguanidine ((131)I-MIBG) with carboplatin, etoposide, melphalan (CEM) and autologous stem-cell transplantation (ASCT) in refractory neuroblastoma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:FrancBenjaminB,
pubmed-author:GroshenSusanS,
pubmed-author:HornBiljanaB,
pubmed-author:MarisJohn MJM,
pubmed-author:MatthayKatherine KKK,
pubmed-author:ReynoldsC PatrickCP,
pubmed-author:SeegerRobert CRC,
pubmed-author:TanJessica CJC,
pubmed-author:TwomeyEilishE,
pubmed-author:VeatchJanetJ,
pubmed-author:VillablancaJudith GJG,
pubmed-author:YanikGregory AGA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
500-6
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:16421427-3-Iodobenzylguanidine,
pubmed-meshheading:16421427-Adolescent,
pubmed-meshheading:16421427-Antineoplastic Agents,
pubmed-meshheading:16421427-Carboplatin,
pubmed-meshheading:16421427-Child,
pubmed-meshheading:16421427-Child, Preschool,
pubmed-meshheading:16421427-Disease-Free Survival,
pubmed-meshheading:16421427-Drug Administration Schedule,
pubmed-meshheading:16421427-Etoposide,
pubmed-meshheading:16421427-Female,
pubmed-meshheading:16421427-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:16421427-Humans,
pubmed-meshheading:16421427-Male,
pubmed-meshheading:16421427-Melphalan,
pubmed-meshheading:16421427-Neuroblastoma,
pubmed-meshheading:16421427-Survival Analysis,
pubmed-meshheading:16421427-Transplantation, Autologous,
pubmed-meshheading:16421427-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
|
|
pubmed:affiliation |
Department of Pediatrics, University of California, San Francisco, School of Medicine, and UCSF Children's Hospital, San Francisco, CA 94143-0106, USA. matthayk@peds.ucsf.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I,
Research Support, N.I.H., Extramural
|
